The DOI matches its Crossref record; 257 of the 257 references it cites were found in a registry or an index.
Glioblastoma multiforme: State of the art and future therapeutics
Open accessAbstract
BACKGROUND: Glioblastoma multiforme (GBM) is the most common and lethal primary malignancy of the central nervous system (CNS). Despite the proven benefit of surgical resection and aggressive treatment with chemo- and radiotherapy, the prognosis remains very poor. Recent advances of our understanding of the biology and pathophysiology of GBM have allowed the development of a wide array of novel therapeutic approaches, which have been developed. These novel approaches include molecularly targeted therapies, immunotherapies, and gene therapy. METHODS: We offer a brief review of the current standard of care, and a survey of novel therapeutic approaches for treatment of GBM. RESULTS: Despite promising results in preclinical trials, many of these therapies have demonstrated limited therapeutic efficacy in human clinical trials. Thus, although survival of patients with GBM continues to slowly improve, treatment of GBM remains extremely challenging. CONCLUSION: Continued research and development of targeted therapies, based on a detailed understanding of molecular pathogenesis can reasonably be expected to yield improved outcomes for patients with GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 1×
“[168,199] Vascular endothelial growth factor (VEGF), a critical mediator of angiogenesis, is highly overexpressed in GBM.[31,62,68,69,165,184] VEGF has been correlated with clinical outcomes, including time to recurrence and survival.”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · cited 11×
“[268] Genetic alterations more typical for primary GBM are epidermal growth factor receptor (EGFR) overexpression, PTEN mutations, and loss of chromosome 10.[75,159,161,258] Whereas genetic alterations more commonly seen in secondary GBM include isocitrate dehydrogenase‐1 (IDH1) mutations, TP53 mutations, and 19q loss.”
BackgroundInfluentialIdentification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 1×
“[160] In 2008, it was reported that IDH1 mutations occur in a disproportionately large portion of younger patients and in the majority of patients with secondary GBM.[164] Additionally, IDH1 mutations appear to be associated with better prognosis and increase in overall survival.”
BackgroundIDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423 · cited 2×
“This fluorescence can be used to guide tumor resection by identifying tumor tissue that may otherwise appear normal.[4,97,171,232] Studies comparing fluorescence‐guided resection with standard white light resection have shown that patients undergoing fluorescence‐guided resection were more likely to have a gross total…”
BackgroundMethodPhillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Cahoy, J. D., Emery, B., Kaushal, A., Foo, L. C., Zamanian, J. L., Christopherson, K. S., Xing, Y., Lubischer, J. L., Krieg, P. A., Krupenko, S. A., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4178-07.2008 · Cited by 3,129 · cited 4×
“It is strongly enriched in the gene expression pattern seen in neurons, and expresses both astrocytic and oligodendrocytic markers.[23,258]”
BackgroundInfluentialBevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
A restricted cell population propagates glioblastoma growth after chemotherapy
Chen, J., Li, Y., Yu, T.-S., McKay, R. M., Burns, D. K., Kernie, S. G., & Parada, L. F. (2012) · Nature · doi:10.1038/nature11287 · Cited by 2,354
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316 · cited 2×
“[23,258] It is characterized by alterations in TP53, platelet‐derived growth factor receptor (PDGFR), and IDH1.[7,77,118,258,268,280] Although overexpression of PDGFR is observed in many GBMs, focal amplification of PDGFR with resultantly high levels of PDGFR expression is most frequently seen in the proneural subtype.”
BackgroundLee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N. M., Pastorino, S., Purow, B. W., Christopher, N., Zhang, W., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.030 · Cited by 2,311
A Perivascular Niche for Brain Tumor Stem Cells
Calabrese, C., Poppleton, H., Kocak, M., Hogg, T. L., Fuller, C., Hamner, B., Oh, E. Y., Gaber, M. W., Finklestein, D., Allen, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.020 · Cited by 2,197
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 1×
“Accordingly, inhibitors of farnesyl transferase, including tipifarnib and lonafarnib, have been investigated in GBM.[40,218,223] Preclinical studies have shown reduced signaling through the RAS pathway, but in clinical trials, they have not provided benefit.”
BackgroundPresta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Dvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,573
Genetic Pathways to Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070011 · Cited by 1,497
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2175 · Cited by 1,405
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., Cenci, T., Maira, G., Parati, E. A., Stassi, G., Larocca, L. M., et al. (2010) · Nature · doi:10.1038/nature09557 · Cited by 1,379
Westphal, M., Hilt, D. C., Bortey, E., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jääskeläinen, J., & Ram, Z. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.79 · Cited by 1,330
Genetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.-L., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,270
Glioblastoma stem-like cells give rise to tumour endothelium
Wang, R., Chadalavada, K., Wilshire, J., Kowalik, U., Hovinga, K. E., Geber, A., Fligelman, B., Leversha, M., Brennan, C., & Tabar, V. (2010) · Nature · doi:10.1038/nature09624 · Cited by 1,203
Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells
Piccirillo, S. G. M., Reynolds, B. A., Zanetti, N., Lamorte, G., Binda, E., Broggi, G., Brem, H., Olivi, A., Dimeco, F., & Vescovi, A. L. (2006) · Nature · doi:10.1038/nature05349 · Cited by 1,176
The Definition of Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3002 · Cited by 1,132
Targeting the mitogen-activated protein kinase cascade to treat cancer
Sebolt-Leopold, J. S., & Herrera, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1503 · Cited by 1,108
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,078
Beroukhim, R., Getz, G., Nghiemphu, L., Barretina, J., Hsueh, T., Linhart, D., Vivanco, I., Lee, J. C., Huang, J. H., Alexander, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710052104 · Cited by 1,075
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027 · cited 2×
“[7,77,118,155,159‐161,268,280] Although different gene expression patterns in primary and secondary GBM were identified, characterization of the IDH1 mutation has allowed for reliable molecular differentiation of primary from secondary GBM.[9,158,160,269,280]”
BackgroundPollard, S. M., Yoshikawa, K., Clarke, I. D., Danovi, D., Stricker, S., Russell, R., Bayani, J., Head, R., Lee, M., Bernstein, M., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.03.014 · Cited by 1,025
Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
Kirson, E. D., Dbalý, V., Tovaryš, F., Vymazal, J., Soustiel, J. F., Itzhaki, A., Mordechovich, D., Steinberg-Shapira, S., Gurvich, Z., Schneiderman, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702916104 · Cited by 894
Temozolomide: Mechanisms of Action, Repair and Resistance
Zhang, J., F.G. Stevens, M., & D. Bradshaw, T. (2012) · Current Molecular Pharmacology · doi:10.2174/1874467211205010102 · Cited by 885
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain
Sun, L., Hui, A.-M., Su, Q., Vortmeyer, A., Kotliarov, Y., Pastorino, S., Passaniti, A., Menon, J., Walling, J., Bailey, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.003 · Cited by 877
Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K. D., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., Mitchell, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6963 · Cited by 815
MGMT: its role in cancer aetiology and cancer therapeutics
Gerson, S. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1319 · Cited by 813
Lewis, P. F., & Emerman, M. (1994) · Journal of Virology · doi:10.1128/jvi.68.1.510-516.1994 · Cited by 797
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., Shi, Y.-X., Levin, V. A., Yung, W. K. A., & Kyritsis, A. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203251 · Cited by 764
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
Wan, X., Harkavy, B., Shen, N., Grohar, P., & Helman, L. J. (2007) · Oncogene · doi:10.1038/sj.onc.1209990 · Cited by 755
Watanabe, K., Tachibana, O., Sato, K., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00848.x · Cited by 740
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734
Murat, A., Migliavacca, E., Gorlia, T., Lambiv, W. L., Shay, T., Hamou, M.-F., de Tribolet, N., Regli, L., Wick, W., Kouwenhoven, M. C. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7164 · Cited by 721
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Nobusawa, S., Watanabe, T., Kleihues, P., & Ohgaki, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0715 · Cited by 711
Rainov, N. G. (2000) · Human Gene Therapy · doi:10.1089/104303400750038499 · Cited by 698
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
An overview of current delivery systems in cancer gene therapy
El-Aneed, A. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.09.013 · Cited by 693
SSEA-1 Is an Enrichment Marker for Tumor-Initiating Cells in Human Glioblastoma
Son, M. J., Woolard, K., Nam, D.-H., Lee, J., & Fine, H. A. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.03.003 · Cited by 672
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J. J., DeVroom, H. L., Otto, E., Long, Z., Chiang, Y., McGarrity, G. J., Muul, L. M., et al. (1997) · Nature Medicine · doi:10.1038/nm1297-1354 · Cited by 668
Kaina, B., Christmann, M., Naumann, S., & Roos, W. P. (2007) · DNA Repair · doi:10.1016/j.dnarep.2007.03.008 · Cited by 663
Notch Promotes Radioresistance of Glioma Stem Cells
Wang, J., Wakeman, T. P., Lathia, J. D., Hjelmeland, A. B., Wang, X.-F., White, R. R., Rich, J. N., & Sullenger, B. A. (2010) · Stem Cells · doi:10.1002/stem.261 · Cited by 656
Alkylation damage in DNA and RNA—repair mechanisms and medical significance
Drabløs, F., Feyzi, E., Aas, P. A., Vaagbø, C. B., Kavli, B., Bratlie, M. S., Peña-Diaz, J., Otterlei, M., Slupphaug, G., & Krokan, H. E. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.05.004 · Cited by 648
Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593
Primary and secondary glioblastomas: From concept to clinical diagnosis
Kleihues, P., & Ohgaki, H. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.1.44 · Cited by 586
VEGF as a Therapeutic Target in Cancer
Ferrara, N. (2005) · Oncology · doi:10.1159/000088479 · Cited by 578
van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clement, P. M., Frenay, M., Campone, M., Baurain, J.-F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 575
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
KOMOTAR, R. J., WILSON, D. A., & CONNOLLY, E. S. (2005) · Neurosurgery · doi:10.1093/neurosurgery/57.1.n7a · Cited by 570
Liau, L. M., Prins, R. M., Kiertscher, S. M., Odesa, S. K., Kremen, T. J., Giovannone, A. J., Lin, J.-W., Chute, D. J., Mischel, P. S., Cloughesy, T. F., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0464 · Cited by 543
Yu, J. S., Liu, G., Ying, H., Yong, W. H., Black, K. L., & Wheeler, C. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3505 · Cited by 537
Brennan, C., Momota, H., Hambardzumyan, D., Ozawa, T., Tandon, A., Pedraza, A., & Holland, E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007752 · Cited by 534
Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells
Chen, J., McKay, R. M., & Parada, L. F. (2012) · Cell · doi:10.1016/j.cell.2012.03.009 · Cited by 527
Batchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520
Yu, J. S., Wheeler, C. J., Zeltzer, P. M., Ying, H., Nacis-Finger, D., Lee, P.-K., Yong, W. H., Incardona, F., Thompson, R. C., Riedinger, M. S., et al. (2001) · PubMed · Cited by 510
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
Kunwar, S., Chang, S., Westphal, M., Vogelbaum, M., Sampson, J., Barnett, G., Shaffrey, M., Ram, Z., Piepmeier, J., Prados, M., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop054 · Cited by 483
Reardon, D. A., Fink, K. L., Mikkelsen, T., Cloughesy, T. F., O'Neill, A., Plotkin, S., Glantz, M., Ravin, P., Raizer, J. J., Rich, K. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7510 · Cited by 481
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465
Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing
Todo, T., Martuza, R. L., Rabkin, S. D., & Johnson, P. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101136398 · Cited by 465
Shapiro, W. R., Green, S. B., Burger, P. C., Mahaley, M. S., Selker, R. G., VanGilder, J. C., Robertson, J. T., Ransohoff, J., Mealey, J., Strike, T. A., et al. (1989) · Journal of Neurosurgery · doi:10.3171/jns.1989.71.1.0001 · Cited by 458
Stupp, R., Hegi, M. E., Neyns, B., Goldbrunner, R., Schlegel, U., Clement, P. M. J., Grabenbauer, G. G., Ochsenbein, A. F., Simon, M., Dietrich, P.-Y., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6650 · Cited by 454
MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma
Verma, A. (2006) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(08)70328-4 · Cited by 452
Prins, R. M., Soto, H., Konkankit, V., Odesa, S. K., Eskin, A., Yong, W. H., Nelson, S. F., & Liau, L. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2563 · Cited by 451
Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Wen, P. Y., Yung, W. K. A., Lamborn, K. R., Dahia, P. L., Wang, Y., Peng, B., Abrey, L. E., Raizer, J., Cloughesy, T. F., Fink, K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0773 · Cited by 429
Antibody Conjugate Therapeutics: Challenges and Potential
Teicher, B. A., & Chari, R. V. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1417 · Cited by 427
Markert, J. M., Liechty, P. G., Wang, W., Gaston, S., Braz, E., Karrasch, M., Nabors, L. B., Markiewicz, M., Lakeman, A. D., Palmer, C. A., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.228 · Cited by 401
Immonen, A., Vapalahti, M., Tyynelä, K., Hurskainen, H., Sandmair, A., Vanninen, R., Langford, G., Murray, N., & Ylä-Herttuala, S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.08.002 · Cited by 390
Prados, M. D., Chang, S. M., Butowski, N., DeBoer, R., Parvataneni, R., Carliner, H., Kabuubi, P., Ayers-Ringler, J., Rabbitt, J., Page, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9639 · Cited by 378
Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma
Stupp, R., Hegi, M. E., van den Bent, M. J., Mason, W. P., Weller, M., Mirimanoff, R. O., Cairncross, J. G., & on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-165 · Cited by 373
HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression
Curtin, J. F., Liu, N., Candolfi, M., Xiong, W., Assi, H., Yagiz, K., Edwards, M. R., Michelsen, K. S., Kroeger, K. M., Liu, C., et al. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000010 · Cited by 364
Radiation therapy for neoplasms of the brain
Leibel, S. A., & Sheline, G. E. (1987) · Journal of Neurosurgery · doi:10.3171/jns.1987.66.1.0001 · Cited by 357
Fueyo, J., Alemany, R., Gomez-Manzano, C., Fuller, G. N., Khan, A., Conrad, C. A., Liu, T.-J., Jiang, H., Lemoine, M. G., Suzuki, K., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.652 · Cited by 350
Mesnil, M., & Yamasaki, H. (2000) · PubMed · Cited by 345
αvβ3 and αvβ5 Integrin Expression in Glioma Periphery
Bello, L., Francolini, M., Marthyn, P., Zhang, J., Carroll, R. S., Nikas, D. C., Strasser, J. F., Villani, R., Cheresh, D. A., & Black, P. M. (2001) · Neurosurgery · doi:10.1097/00006123-200108000-00022 · Cited by 341
Parker, J. N., Gillespie, G. Y., Love, C. E., Randall, S., Whitley, R. J., & Markert, J. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040557897 · Cited by 332
Glioma Stem Cells: A Midterm Exam
Stiles, C. D., & Rowitch, D. H. (2008) · Neuron · doi:10.1016/j.neuron.2008.05.031 · Cited by 330
Reardon, D. A., Egorin, M. J., Quinn, J. A., Rich, J. N., Gururangan, I., Vredenburgh, J. J., Desjardins, A., Sathornsumetee, S., Provenzale, J. M., Herndon, J. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2185 · Cited by 330
Gene expression profiling identifies molecular subtypes of gliomas
Shai, R., Shi, T., Kremen, T. J., Horvath, S., Liau, L. M., Cloughesy, T. F., Mischel, P. S., & Nelson, S. F. (2003) · Oncogene · doi:10.1038/sj.onc.1206753 · Cited by 328
VEGF-A: a critical regulator of blood vessel growth
Ferrara, N. (2009) · European Cytokine Network · doi:10.1684/ecn.2009.0170 · Cited by 327
PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma
Östman, A. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.002 · Cited by 326
Pichlmeier, U., Bink, A., Schackert, G., & Stummer, W. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-052 · Cited by 326
Kunwar, S., Prados, M. D., Chang, S. M., Berger, M. S., Lang, F. F., Piepmeier, J. M., Sampson, J. H., Ram, Z., Gutin, P. H., Gibbons, R. D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1117 · Cited by 325
Molecularly targeted therapy for malignant glioma
Sathornsumetee, S., Reardon, D. A., Desjardins, A., Quinn, J. A., Vredenburgh, J. J., & Rich, J. N. (2007) · Cancer · doi:10.1002/cncr.22741 · Cited by 325
IDH1 and IDH2 Mutations in Gliomas
Uhm, J. (2009) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(09)79085-4 · Cited by 322
Kamoun, W. S., Ley, C. D., Farrar, C. T., Duyverman, A. M., Lahdenranta, J., Lacorre, D. A., Batchelor, T. T., di Tomaso, E., Duda, D. G., Munn, L. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9356 · Cited by 309 · cited 1×
“Despite encouraging results in preclinical trials, clinical trials with these agents have demonstrated limited therapeutic benefit, and in some trials, were associated with high toxicity rates.[12,110,156,194,198] In clinical trials, similar to cedarinib and sunitinib, vatalanib, an oral inhibitor of VEGF and PDGFR, p…”
ResultSandmair, A.-M., Loimas, S., Puranen, P., Immonen, A., Kossila, M., Puranen, M., Hurskainen, H., Tyynelä, K., Turunen, M., Vanninen, R., et al. (2000) · Human Gene Therapy · doi:10.1089/104303400750035726 · Cited by 300
McGirt, M. J., Than, K. D., Weingart, J. D., Chaichana, K. L., Attenello, F. J., Olivi, A., Laterra, J., Kleinberg, L. R., Grossman, S. A., Brem, H., et al. (2009) · Journal of Neurosurgery · doi:10.3171/2008.5.17557 · Cited by 299
Raizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Yung, W. K. A., Gilbert, M. R., Aldape, K. A., Wen, P. Y., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop015 · Cited by 299
Schmidt, N. O., Westphal, M., Hagel, C., Erg�n, S., Stavrou, D., Rosen, E. M., & Lamszus, K. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990219)84:1<10::aid-ijc3>3.0.co;2-l · Cited by 296
Sampson, J. H., Archer, G. E., Mitchell, D. A., Heimberger, A. B., Herndon, J. E., Lally-Goss, D., McGehee-Norman, S., Paolino, A., Reardon, D. A., Friedman, A. H., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0124 · Cited by 287
Recent Advances in Therapy for Glioblastoma
Clarke, J., Butowski, N., & Chang, S. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.5 · Cited by 283
Forsyth, P., Roldán, G., George, D., Wallace, C., Palmer, C. A., Morris, D., Cairncross, G., Matthews, M. V., Markert, J., Gillespie, Y., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300403 · Cited by 278
Brown, P. D., Krishnan, S., Sarkaria, J. N., Wu, W., Jaeckle, K. A., Uhm, J. H., Geoffroy, F. J., Arusell, R., Kitange, G., Jenkins, R. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0612 · Cited by 277
Identification of molecular subtypes of glioblastoma by gene expression profiling
Mischel, P. S., Shai, R., Shi, T., Horvath, S., Lu, K. V., Choe, G., Seligson, D., Kremen, T. J., Palotie, A., Liau, L. M., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206344 · Cited by 272
De Vleeschouwer, S., Fieuws, S., Rutkowski, S., Van Calenbergh, F., Van Loon, J., Goffin, J., Sciot, R., Wilms, G., Demaerel, P., Warmuth-Metz, M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4875 · Cited by 271
Gene Therapy with Viral Vectors
Kootstra, N. A., & Verma, I. M. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140257 · Cited by 267 · cited 6×
“[119] They contain a reverse transcriptase that, following transduction, allows them to integrate their genetic material in the host DNA.[119] Retroviruses selectively infect actively dividing cells, which allows them to target rapidly dividing GBM cells while sparing normal brain cells.”
BackgroundInfluentialArmah, H. B. (2010) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/s1077-9108(09)79430-7 · Cited by 266
Yamanaka, R., Abe, T., Yajima, N., Tsuchiya, N., Homma, J., Kobayashi, T., Narita, M., Takahashi, M., & Tanaka, R. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601268 · Cited by 265
Trask, T. W., Trask, R. P., Aguilar-Cordova, E., Shine, H. D., Wyde, P. R., Goodman, J. C., Hamilton, W. J., Rojas-Martinez, A., Chen, S.-H., Woo, S. L. C., et al. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0030 · Cited by 262
Development of lentiviral vectors for gene therapy for human diseases
Buchschacher, G. L., & Wong-Staal, F. (2000) · Blood · doi:10.1182/blood.v95.8.2499 · Cited by 261
Integrins: The Keys to Unlocking Angiogenesis
Silva, R., D'Amico, G., Hodivala-Dilke, K. M., & Reynolds, L. E. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.172015 · Cited by 255
van den Bent, M. J., Dubbink, H. J., Sanson, M., van der Lee-Haarloo, C. R., Hegi, M., Jeuken, J. W. M., Ibdaih, A., Brandes, A. A., Taphoorn, M. J. B., Frenay, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1034 · Cited by 255
Intratumoral LAK cell and interleukin-2 therapy of human gliomas
Barba, D., Saris, S. C., Holder, C., Rosenberg, S. A., & Oldfield, E. H. (1989) · Journal of Neurosurgery · doi:10.3171/jns.1989.70.2.0175 · Cited by 252
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
Neyns, B., Sadones, J., Joosens, E., Bouttens, F., Verbeke, L., Baurain, J.-F., D'Hondt, L., Strauven, T., Chaskis, C., In't Veld, P., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp032 · Cited by 250
Shand, N., Weber, F., Mariani, L., Bernstein, M., Gianella-Borradori, A., Long, Z., Sorensen, A. G., & Barbier, N. (1999) · Human Gene Therapy · doi:10.1089/10430349950016979 · Cited by 247
Sloan, A. E., Ahluwalia, M. S., Valerio-Pascua, J., Manjila, S., Torchia, M. G., Jones, S. E., Sunshine, J. L., Phillips, M., Griswold, M. A., Clampitt, M., et al. (2013) · Journal of Neurosurgery · doi:10.3171/2013.1.jns1291 · Cited by 246
Sampson, J. H., Akabani, G., Archer, G. E., Bigner, D. D., Berger, M. S., Friedman, A. H., Friedman, H. S., Herndon II, J. E., Kunwar, S., Marcus, S., et al. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1026290315809 · Cited by 239
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
Uhm, J. (2009) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(09)79089-1 · Cited by 239
Raymond, E., Brandes, A. A., Dittrich, C., Fumoleau, P., Coudert, B., Clement, P. M. J., Frenay, M., Rampling, R., Stupp, R., Kros, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9235 · Cited by 227
Rand, R. W., Kreitman, R. J., Patronas, N., Varricchio, F. E., Pastan, I. H., & Puri, R. K. (2000) · PubMed · Cited by 222
Reovirus as an Oncolytic Agent Against Experimental Human Malignant Gliomas
Wilcox, M. E., Yang, W., Senger, D. L., Rewcastle, N. B., Morris, D. G., Brasher, P. M. A., Shi, Z. Q., Johnston, R. N., Nishikawa, S., Lee, P. W. K., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.12.903 · Cited by 218
Prados, M. D., Lamborn, K. R., Chang, S., Burton, E., Butowski, N., Malec, M., Kapadia, A., Rabbitt, J., Page, M. S., Fedoroff, A., et al. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000451 · Cited by 218
Debinski, W., Obiri, N. I., Powers, S. K., Pastan, I. H., & Puri, R. K. (1995) · PubMed · Cited by 216
Chinot, O. L., Barrié, M., Fuentes, S., Eudes, N., Lancelot, S., Metellus, P., Muracciole, X., Braguer, D., Ouafik, L., Martin, P.-M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.4807 · Cited by 212
Reardon, D. A., Nabors, L. B., Stupp, R., & Mikkelsen, T. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.8.1225 · Cited by 206
Peereboom, D. M., Shepard, D. R., Ahluwalia, M. S., Brewer, C. J., Agarwal, N., Stevens, G. H. J., Suh, J. H., Toms, S. A., Vogelbaum, M. A., Weil, R. J., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0067-2 · Cited by 205
Kikuchi, T., Akasaki, Y., Abe, T., Fukuda, T., Saotome, H., Ryan, J. L., Kufe, D. W., & Ohno, T. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200411000-00005 · Cited by 204
Chinot, O. L., de La Motte Rouge, T., Moore, N., Zeaiter, A., Das, A., Phillips, H., Modrusan, Z., & Cloughesy, T. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0007-3 · Cited by 195
Hayes, R. L., Koslow, M., Hiesiger, E. M., Hymes, K. B., Moore, E. J., Pierz, D. M., Hochster, H. S., Chen, D. K., Budzilovich, G. N., & Ransohoff, J. (1995) · Cancer · doi:10.1002/1097-0142(19950901)76:5<840::aid-cncr2820760519>3.0.co;2-r · Cited by 194
Chambers, R., Gillespie, G. Y., Soroceanu, L., Andreansky, S., Chatterjee, S., Chou, J., Roizman, B., & Whitley, R. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1411 · Cited by 192
Uhm, J. H., Ballman, K. V., Wu, W., Giannini, C., Krauss, J. C., Buckner, J. C., James, C. D., Scheithauer, B. W., Behrens, R. J., Flynn, P. J., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.01.070 · Cited by 192
Chaudhry, I. H., O'Donovan, D. G., Brenchley, P. E. C., Reid, H., & Roberts, I. S. D. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01230.x · Cited by 188
Fujisawa, H., Reis, R. M., Nakamura, M., Colella, S., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780009 · Cited by 180
Pelloski, C. E., Lin, E., Zhang, L., Yung, W. K. A., Colman, H., Liu, J.-L., Woo, S. Y., Heimberger, A. B., Suki, D., Prados, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2202 · Cited by 179
Neural Stem Cell Tropism to Glioma: Critical Role of Tumor Hypoxia
Zhao, D., Najbauer, J., Garcia, E., Metz, M. Z., Gutova, M., Glackin, C. A., Kim, S. U., & Aboody, K. S. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0146 · Cited by 175
Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series
Dresemann, G. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi317 · Cited by 174
A microarray-based DNA methylation study of glioblastoma multiforme
Martinez, R., Martin-Subero, J. I., Rohde, V., Kirsch, M., Alaminos, M., Fernández, A. F., Ropero, S., Schackert, G., & Esteller, M. (2009) · Epigenetics · doi:10.4161/epi.9130 · Cited by 173
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
Sampson, J. H., Archer, G. E., Mitchell, D. A., Heimberger, A. B., & Bigner, D. D. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2008.04.001 · Cited by 172
Brain Tumor Stem Cells: Bringing Order to the Chaos of Brain Cancer
Dirks, P. B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.6792 · Cited by 171
Quattrocchi, K. B., Miller, C. H., Cush, S., Bernard, S. A., Dull, S. T., Smith, M., Gudeman, S., & Varia, M. A. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006293606710 · Cited by 168
Caruso, D. A., Orme, L. M., Neale, A. M., Radcliff, F. J., Amor, G. M., Maixner, W., Downie, P., Hassall, T. E., Tang, M. L. K., & Ashley, D. M. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000668 · Cited by 165 · cited 1×
“Overall, DC vaccines appear to be well tolerated, but have not yet resulted in significant therapeutic benefit.[5,6,27,30,48,115,132,136,181,278,279,281,282]”
BackgroundPrasad, G., Sottero, T. L., Yang, X., Mueller, S., James, C. D., Weiss, W. A., Polley, M. Y., Ozawa, T., Berger, M. S., Aftab, D. T., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq193 · Cited by 165
T cell adoptive immunotherapy of newly diagnosed gliomas.
Plautz, G. E., Miller, D. W., Barnett, G. H., Stevens, G. H., Maffett, S., Kim, J., Cohen, P. A., & Shu, S. (2000) · PubMed · Cited by 159
Schwarzmaier, H., Eickmeyer, F., von Tempelhoff, W., Fiedler, V. U., Niehoff, H., Ulrich, S. D., Yang, Q., & Ulrich, F. (2006) · European Journal of Radiology · doi:10.1016/j.ejrad.2006.05.010 · Cited by 159
Molecular targeting of glioblastoma: Drug discovery and therapies
Bai, R.-Y., Staedtke, V., & Riggins, G. J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.011 · Cited by 158
Ohgaki, H., Watanabe, K., Tachibana, O., Sato, K., & Kleihues, P. (1996) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199605000-00017 · Cited by 155
Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo.
Yamamoto, M., Sawaya, R. A., Mohanam, S., Bindal, A. K., Bruner, J. M., Oka, K., Rao, V. H., Tomonaga, M., Nicolson, G. L., & Rao, J. S. (1994) · PubMed · Cited by 154
Cloughesy, T. F., Wen, P. Y., Robins, H. I., Chang, S. M., Groves, M. D., Fink, K., Junck, L., Schiff, D., Abrey, L. E., Gilbert, M. R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2323 · Cited by 154
Anton, K., Baehring, J. M., & Mayer, T. M. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.04.006 · Cited by 153
Chang, C.-N., Huang, Y.-C., Yang, D.-M., Kikuta, K., Wei, K.-J., Kubota, T., & Yang, W.-K. (2011) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2010.11.034 · Cited by 151
Germano, I. M., Fable, J., Gultekin, S. H., & Silvers, A. (2003) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000003657.95085.56 · Cited by 148
EGFRvIII‐Targeted Vaccination Therapy of Malignant Glioma
Choi, B. D., Archer, G. E., Mitchell, D. A., Heimberger, A. B., McLendon, R. E., Bigner, D. D., & Sampson, J. H. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00318.x · Cited by 148
Ardon, H., Gool, S. V., Lopes, I. S., Maes, W., Sciot, R., Wilms, G., Demaerel, P., Bijttebier, P., Claes, L., Goffin, J., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0131-y · Cited by 147
PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors
Mellinghoff, I. K., Cloughesy, T. F., & Mischel, P. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1992 · Cited by 146
Systemic T cell adoptive immunotherapy of malignant gliomas
Plautz, G. E., Barnett, G. H., Miller, D. W., Cohen, B. H., Prayson, R. A., Krauss, J. C., Luciano, M. G., Kangisser, D., & Shu, S. (1998) · Journal of neurosurgery · doi:10.3171/jns.1998.89.1.0042 · Cited by 146
Vredenburgh, J. J., Desjardins, A., Reardon, D. A., Peters, K. B., Herndon, J. E., Marcello, J. E., Kirkpatrick, J. P., Sampson, J. H., Bailey, L., Threatt, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0120 · Cited by 146
Phase II study of sunitinib malate in patients with recurrent high-grade glioma
Neyns, B., Sadones, J., Chaskis, C., Dujardin, M., Everaert, H., Lv, S., Duerinck, J., Tynninen, O., Nupponen, N. N., Michotte, A., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0402-7 · Cited by 144
Adjuvant dendritic cell‐based tumour vaccination for children with malignant brain tumours
Ardon, H., Vleeschouwer, S. D., Calenbergh, F. V., Claes, L., Kramm, C. M., Rutkowski, S., Wolff, J. E. A., & Gool, S. W. V. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22319 · Cited by 144
Beltinger, C., Fulda, S., Kammertoens, T., Meyer, E., Uckert, W., & Debatin, K.-M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8699 · Cited by 143
Debinski, W., & Gibo, D. M. (2000) · Molecular Medicine · doi:10.1007/bf03401786 · Cited by 142
Reardon, D. A., Dresemann, G. P., Taillibert, S., Campone, M., van den Bent, M. J., Clément, P. M., Blomquist, E., Gordower, L., Schultz, H., Raizer, J. J., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605411 · Cited by 141
Loss of Heterozygosity on Chromosome 19 in Secondary Glioblastomas
Nakamura, M., Yang, F., Fujisawa, H., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.6.539 · Cited by 141
Geoerger, B., Grill, J., Opolon, P., Morizet, J., Aubert, G., Terrier‐Lacombe, M., Paillerets, B. B., Barrois, M., Feunteun, J., Kirn, D. H., et al. (2002) · PubMed · Cited by 140
Li, L., Quang, T. S., Gracely, E., Kim, J. H., Emrich, J., Yaeger, T. E., Jenrette, J. M., Cohen, S. C., Black, P., & Brady, L. W. (2010) · Journal of neurosurgery · doi:10.3171/2010.2.jns091211 · Cited by 139
Ahmed, A. U., Tyler, M. A., Thaçi, B., Alexiades, N. G., Han, Y., Ulasov, I. V., & Lesniak, M. S. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200161f · Cited by 137
Yajima, N., Yamanaka, R., Mine, T., Tsuchiya, N., Homma, J., Sano, M., Kuramoto, T., Obata, Y., Komatsu, N., Arima, Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0559 · Cited by 133
Ahmed, A. U., Thaçi, B., Alexiades, N. G., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.100 · Cited by 132
Dillman, R. O., Duma, C., Schiltz, P. M., DePriest, C. B., Ellis, R. A., Okamoto, K., Beutel, L. D., de Leon, C., & Chico, S. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200409000-00009 · Cited by 122
Gene Therapy and Targeted Toxins for Glioma
King, G. D., Curtin, J. F., Candolfi, M., Kroeger, K. M., Lowenstein, P. R., & Castro, M. G. (2005) · Current Gene Therapy · doi:10.2174/156652305774964631 · Cited by 122
Msaouel, P., Dispenzieri, A. A., & Galanis, E. (2009) · PubMed · Cited by 118
Oncolytic Viruses: Clinical Applications as Vectors for the Treatment of Malignant Gliomas
Shah, A. C., Benos, D. J., Gillespie, G. Y., & Markert, J. M. (2003) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000003651.97832.6c · Cited by 116
Terada, K., Wakimoto, H., Tyminski, E., Chiocca, E. A., & Saeki, Y. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302717 · Cited by 113
Eller, J. L., Longo, S. L., Kyle, M. M., Bassano, D. A., Hicklin, D. J., & Canute, G. W. (2005) · Neurosurgery · doi:10.1227/01.neu.0000145865.25689.55 · Cited by 110
The art of gene therapy for glioma: a review of the challenging road to the bedside
Tobias, A. L., Ahmed, A. U., Moon, K., & Lesniak, M. S. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302946 · Cited by 110
Neural Stem Cell Targeting of Glioma Is Dependent on Phosphoinositide 3-Kinase Signaling
Kendall, S. E., Najbauer, J., Johnston, H. F., Metz, M. Z., Li, S., Bowers, M., Garcia, E., Kim, S. U., Barish, M. E., Aboody, K. S., et al. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0887 · Cited by 110
Smitt, P. A. E. S., Driesse, M. J., Wolbers, J. G., Kros, M., & Avezaat, C. J. J. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00100-x · Cited by 110
Overview of Cellular Immunotherapy for Patients with Glioblastoma
Vauléon, É., Avril, T., Collet, B., Mosser, J., & Quillien, V. (2010) · Journal of Immunology Research · doi:10.1155/2010/689171 · Cited by 110
Intralesional Lymphokine-activated Killer Cells as Adjuvant Therapy for Primary Glioblastoma
Dillman, R. O., Duma, C., Ellis, R. A., Cornforth, A. N., Schiltz, P. M., Sharp, S. L., & DePriest, C. B. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b2910f · Cited by 109
Harsh, G. R., Deisboeck, T. S., Louis, D. N., et al. (2000) · Journal of neurosurgery · doi:10.3171/jns.2000.92.5.0804 · Cited by 109
Release of HMGB1 in Response to Proapoptotic Glioma Killing Strategies: Efficacy and Neurotoxicity
Candolfi, M., Yagiz, K., Foulad, D. S., Alzadeh, G. E., Tesarfreund, M., Muhammad, A. K. M. G., Puntel, M., Kroeger, K. M., Liu, C., Lee, S. C. L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0155 · Cited by 108
Gilbert, M. R., Dignam, J. J., Won, M., Blumenthal, D. T., Vogelbaum, M. A., Aldape, K., Colman, H., Chakravarti, A., Jeraj, R., Armstrong, T. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.1 · Cited by 105
Immunotherapy of malignant brain tumors
Mitchell, D. A., Fecci, P. E., & Sampson, J. H. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00603.x · Cited by 104
Prados, M. D., McDermott, M., Chang, S. M., Wilson, C. B., Fick, J. R., Culver, K. W., Gilder, J. V., Keles, G. E., Spence, A. M., & Berger, M. S. (2003) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000003588.18644.9c · Cited by 101
Schwarzmaier, H., Yaroslavsky, I. V., Yaroslavsky, A. N., Fiedler, V. U., Ulrich, F., & Kahn, T. (1998) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880080124 · Cited by 101
Combs, S. E., Heeger, S., Haselmann, R., Edler, L., Debus, J., & Schulz–Ertner, D. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-133 · Cited by 100
Dendritic Cell Therapy of High‐Grade Gliomas
Gool, S. V., Maes, W., Ardon, H., Verschuere, T., Cauter, S. V., & Vleeschouwer, S. D. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00316.x · Cited by 100
Izquierdo, M., Martı́n, V., de Felipe, P., Jm, I., Përez‐Higueras, A., Cortés, M. L., Jf, P., Isla, A., & Mg, B. (1996) · PubMed · Cited by 98
Immunotherapy for the Treatment of Glioblastoma
Thomas, A. A., Ernstoff, M. S., & Fadul, C. E. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e3182431a73 · Cited by 97
Vallera, D. A., Li, C., Jin, N., Panoskaltsis‐Mortari, A., & Hall, W. A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.8.597 · Cited by 95
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients
Heimberger, A. B., & Sampson, J. H. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903124346 · Cited by 94
Clinical Trials with Retrovirus Mediated Gene Therapy – what Have we Learned?
Rainov, N. G., & Ren, H. (2003) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000003652.71665.f2 · Cited by 91
Reardon, D. A., Egorin, M. J., Desjardins, A., Vredenburgh, J. J., Beumer, J. H., Lagattuta, T. F., Gururangan, S., Herndon, J. E., Salvado, A. J., & Friedman, H. S. (2009) · Cancer · doi:10.1002/cncr.24213 · Cited by 91
Joshi, B. H., Leland, P., Asher, A. L., Prayson, R. A., Varricchio, F. E., & Puri, R. K. (2001) · PubMed · Cited by 90
Cited by
Glioblastoma: Overview of Disease and Treatment
Davis, M. (2016) · Clinical Journal of Oncology Nursing · doi:10.1188/16.cjon.s1.2-8 · Cited by 1,205
Glioblastoma multiforme: Pathogenesis and treatment
Alifieris, C., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 820
Survival in glioblastoma: a review on the impact of treatment modalities
Delgado-López, P. D., & Corrales-García, E. M. (2016) · Clinical and Translational Oncology · doi:10.1007/s12094-016-1497-x · Cited by 659
Epidemiology and Outcome of Glioblastoma
Department of Neurosurgery, J. U. H. A. M. S., TAMIMI, A. F., JUWEID, M., & Department of Radiology and Nuclear Medicine, J. U. H. A. M. S. (2017) · Glioblastoma · doi:10.15586/codon.glioblastoma.2017.ch8 · Cited by 484
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
Strobel, H., Baisch, T., Fitzel, R., Schilberg, K., Siegelin, M. D., Karpel-Massler, G., Debatin, K.-M., & Westhoff, M.-A. (2019) · Biomedicines · doi:10.3390/biomedicines7030069 · Cited by 279
Metadata
- Authors
- Harter, D., Wilson, T., & Karajannis, M.
- Venue
- Surgical Neurology International
- Publisher
- Scientific Scholar
- Published
- 2014
- Volume
- 5
- Issue
- 1
- Pages
- 64
- ISSN
- 2152-7806 (ISSN-L)
- OpenAlex
- W2003438982
- Cited by
- 327
- References
- 257
- FWCI
- 12.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.